Dana-Farber Cancer Institute | Strategic Alliance Partners

October 15, 2020

Matthew S. Davids, MD, MMSc, discusses investigational doublets and triplets in chronic lymphocytic leukemia.

October 14, 2020

Matthew S. Davids, MD, MMSc, discusses the shift away from chemoimmunotherapy in chronic lymphocytic leukemia and ongoing research in the space.

October 13, 2020

Matthew S. Davids, MD, MMSc, discusses selecting between continuous and time-limited therapy in chronic lymphocytic leukemia.

October 12, 2020

Ziad Bakouny, MD, MSc, discusses the rate of disease progression in sarcomatoid carcinoma.

October 09, 2020

Matthew S. Davids, MD, MMSc, discusses factors to consider when selecting treatment for patients with chronic lymphocytic leukemia.

October 08, 2020

Nancy U. Lin, MD, discusses the challenges faced in the treatment of patients with HER2-positive breast cancer and brain metastases.

October 07, 2020

Toni Choueiri, MD, discusses the CheckMate-9ER trial, the next steps for nivolumab/cabozantinib, and other cabozantinib regimens under exploration.

October 07, 2020

The combination of nivolumab plus chemotherapy resulted in a statistically significant improvement in pathologic complete response when used as neoadjuvant treatment in patients with resectable non–small cell lung cancer, meeting the primary end point of the phase 3 CheckMate-816 trial.

October 06, 2020

Matthew S. Davids, MD, MMSc, discusses the use of chemoimmunotherapy in patients with chronic lymphocytic leukemia.

October 06, 2020

Dana-Farber Cancer Institute has launched the Center for Salivary and Rare Head and Neck Cancers to treat patients with rare and occasionally aggressive cancers arising from the head and neck.

October 03, 2020

Sara M. Tolaney, MD, MPH, discusses the phase 2 APT and ATEMPT trials in stage I HER2-positive breast cancer.

October 01, 2020

Sara M. Tolaney, MD, MPH, discusses the evolution of treatment in HER2-positive breast cancer.

September 29, 2020

Paul L. Nguyen, MD, discusses treatment considerations in high-risk prostate cancer.

September 29, 2020

Atish D. Choudhury, MD, PhD, discusses the design of key clinical trials in nonmetastatic castration-resistant prostate cancer.

September 28, 2020

Although frontline chemoimmunotherapy regimens have been the gold standard for patients with chronic lymphocytic leukemia for many years, the advent of BTK inhibitors and other novel drugs has moved the field toward adopting chemotherapy-free options for patients in this setting.

September 25, 2020

Paul L. Nguyen, MD, discusses standard and investigational treatment options in high-risk prostate cancer.

September 24, 2020

In our exclusive interview, Jacob Sands, MD, discusses the FDA approval of lurbinectedin in small cell lung cancer and shed light on key findings from the phase 2 basket trial that served as the basis for the approval.

September 23, 2020

Paul L. Nguyen, MD, discusses the optimal duration of androgen deprivation therapy in patients with high-risk prostate cancer.

September 23, 2020

Atish D. Choudhury, MD, PhD, discusses the goal of treating patients with nonmetastatic castration-resistant prostate cancer.

September 22, 2020

Atish D. Choudhury, MD, PhD, compares the safety profiles of antiandrogen agents in nonmetastatic castration-resistant prostate cancer.